Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Adherence With CDK4/6 Inhibitors
February 19, 2019 – 
Kate Jeffers, PharmD, sums up the importance of patient adherence with CDK4/6 inhibitors and quality metrics used to measure adherence.
Patient Management of CDK4/6 Inhibitors
February 12, 2019 – 
Important touchpoints for patient management of CDK4/6 inhibitors.
Dispensing of CDK4/6 Inhibitors
February 12, 2019 – 
Outlining different dispensing options for CDK4/6 inhibitors including in-clinic, specialty, and medically integrated dispensing.
Multidisciplinary Approach: Managing CDK4/6 Inhibitors
February 05, 2019 – 
Roles of the members of the cross-functional team managing patients taking CDK4/6 inhibitors.
Patients' Perspectives on CDK4/6 Inhibitors
February 05, 2019 – 
Feedback from patients with metastatic breast cancer including their increase in quality of life when taking an oral CDK4/6 inhibitor and the value of continuous dosing of abemaciclib.
Benefits and Challenges of CDK4/6 Inhibitors
January 29, 2019 – 
Benefits and challenges within the CDK4/6 inhibitor class, including adherence.
Metastatic Breast Cancer: CDK4/6 Inhibitors
January 29, 2019 – 
The pros and cons of oral oncolytics versus infusion therapy regarding efficacy, safety, and patient adherence.
Improving Care for Patients With Metastatic Breast Cancer
January 22, 2019 – 
Based on positive feedback on the use of CDK4/6 inhibitors as treatment for metastatic breast cancer, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, NP, remark on strategies for improving adherence to these oral therapies.
Educating Patients and Staff on Using CDK4/6 Inhibitors
January 22, 2019 – 
The value in counseling patients and healthcare professionals on the proper use of CDK4/6 inhibitors for the treatment of metastatic breast cancer.
Best Practices for Managing Patients on CDK4/6 Inhibitors
January 16, 2019 – 
Practical considerations for ensuring that appropriate patients with breast cancer receive and use their oral oncolytic therapies as prescribed.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.